{"protocolSection":{"identificationModule":{"nctId":"NCT02309970","orgStudyIdInfo":{"id":"GR 05 - 14"},"organization":{"fullName":"Rabin Medical Center","class":"OTHER"},"briefTitle":"Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke"},"statusModule":{"statusVerifiedDate":"2014-12","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-12"},"primaryCompletionDateStruct":{"date":"2015-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2016-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2014-12-03","studyFirstSubmitQcDate":"2014-12-04","studyFirstPostDateStruct":{"date":"2014-12-05","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-12-04","lastUpdatePostDateStruct":{"date":"2014-12-05","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Guy Raphaeli","investigatorTitle":"Dr. Guy Raphaeli","investigatorAffiliation":"Rabin Medical Center"},"leadSponsor":{"name":"Rabin Medical Center","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"CT perfusion (CTP) of the brain is an innovative technique to identify rapidly regions which are only partially or insufficiently perfused during an acute ischemic event. The differentiation between the core infarct and the still viable penumbra is its major clinical application. CTP helps directly in the decision-making process in the event of acute ischemic stroke by increasing the potential of success in patient who can benefit from thrombolytic/endovascular treatment.\n\nThe use of CTP in patient selection for thrombolytic/endovascular treatment was never evaluated in a prospective randomized study. Yet, clinical experience well demonstrated a good correlation between the size of the penumbra and the clinical outcome when done in early as well as late stages of the event.\n\nThe importance of identifying the penumbra in the acute phase of the ischemic stroke is widely accepted. But crucial evidence to support the predictive value of CTP to predict the clinical and anatomical/structural outcomes in the late phases (90 days after) is lacking.\n\nCurrently, the use of CTP is based on theoretical assumptions and expert opinions but a randomized prospective study to validate its use is lacking.\n\nThe current guidelines restrict the use of CTP trials and to patients that can't performed MRI scan."},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Conservative","description":"patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology","interventionNames":["Drug: acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran"]},{"label":"IV tPA","description":"patient will receive intravenous thrombolysis treatment","interventionNames":["Drug: alteplase"]},{"label":"Endovascular treatment","description":"patient who will receive endovascular treatment","interventionNames":["Procedure: endovascular"]}],"interventions":[{"type":"DRUG","name":"acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran","description":"subject in this group will receive oral treatment with anti platelet drug","armGroupLabels":["Conservative"],"otherNames":["Aspirin, Plavix, Coumadin, Eliquis,Xarelto, Pradaxa, Sintrom"]},{"type":"DRUG","name":"alteplase","description":"subject in this group will receive intravenous tPA","armGroupLabels":["IV tPA"]},{"type":"PROCEDURE","name":"endovascular","armGroupLabels":["Endovascular treatment"],"otherNames":["subject in this group will undergo mechanical thrombectomy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The predictive value of CTP in identifying penumbra (salvagable brain tissue) in event of ischemic stroke","timeFrame":"three month"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* NIHSS\\>=8\n* up to 6 hours from event onset\n\nExclusion Criteria:\n\n* mRS\\>= 3 before the start of the event\n* life expectency \\<1 year because other disability disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"men and women admittedto the emergency room at Rabin Medical Center, Beilinson Campus and hospitalized at the neurology department.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Guy Raphaeli, MD","role":"CONTACT","phone":"972-50-4065626","email":"guyre@clalit.org.il"},{"name":"Ophir Keret, MD","role":"CONTACT","phone":"972-3-9377080","email":"ophirke@clalit.org.il"}],"overallOfficials":[{"name":"Guy Raphaeli, MD","affiliation":"Rabin Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Rabin Medical Center","city":"Petach Tiqva","state":"Hamerkaz","zip":"49100","country":"Israel","contacts":[{"name":"Guy Raphaeli, MD","role":"CONTACT","phone":"972-50-4065626","email":"guyre@clalit.org.il"}],"geoPoint":{"lat":32.08707,"lon":34.88747}}]},"referencesModule":{"references":[{"pmid":"22075524","type":"BACKGROUND","citation":"Bivard A, Spratt N, Levi C, Parsons M. Perfusion computer tomography: imaging and clinical validation in acute ischaemic stroke. Brain. 2011 Nov;134(Pt 11):3408-16. doi: 10.1093/brain/awr257."},{"pmid":"11546885","type":"RESULT","citation":"Koton S, Bornstein NM, Green MS. Population group differences in trends in stroke mortality in Israel. Stroke. 2001 Sep;32(9):1984-8. doi: 10.1161/hs0901.095407."},{"pmid":"7477192","type":"RESULT","citation":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1581-7. doi: 10.1056/NEJM199512143332401."},{"pmid":"18815396","type":"RESULT","citation":"Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656."},{"pmid":"10591382","type":"RESULT","citation":"Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999 Dec 1;282(21):2003-11. doi: 10.1001/jama.282.21.2003."},{"pmid":"12917889","type":"RESULT","citation":"Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD000213. doi: 10.1002/14651858.CD000213."},{"pmid":"22435369","type":"RESULT","citation":"Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842."},{"pmid":"18705914","type":"RESULT","citation":"Parsons MW. Perfusion CT: is it clinically useful? Int J Stroke. 2008 Feb;3(1):41-50. doi: 10.1111/j.1747-4949.2008.00175.x."},{"pmid":"23264523","type":"RESULT","citation":"Goyal M, Menon BK, Derdeyn CP. Perfusion imaging in acute ischemic stroke: let us improve the science before changing clinical practice. Radiology. 2013 Jan;266(1):16-21. doi: 10.1148/radiol.12112134. No abstract available."},{"pmid":"23493340","type":"RESULT","citation":"Gonzalez RG, Copen WA, Schaefer PW, Lev MH, Pomerantz SR, Rapalino O, Chen JW, Hunter GJ, Romero JM, Buchbinder BR, Larvie M, Hirsch JA, Gupta R. The Massachusetts General Hospital acute stroke imaging algorithm: an experience and evidence based approach. J Neurointerv Surg. 2013 May;5 Suppl 1(Suppl 1):i7-12. doi: 10.1136/neurintsurg-2013-010715. Epub 2013 Mar 14."},{"pmid":"22015331","type":"RESULT","citation":"Abstracts of the 17th European Stroke Conference. Nice, France. May 13-16, 2008. Cerebrovasc Dis. 2008;25 Suppl 2:1-204. doi: 10.1159/000132086. No abstract available."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000010959","term":"Tissue Plasminogen Activator"},{"id":"D000014859","term":"Warfarin"},{"id":"D000069552","term":"Rivaroxaban"},{"id":"D000069604","term":"Dabigatran"},{"id":"C000522181","term":"Apixaban"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Barriers","relevance":"HIGH"},{"id":"M288142","name":"Apixaban","asFound":"Extraction","relevance":"HIGH"},{"id":"M1669","name":"Clopidogrel","asFound":"Carbapenem-resistant","relevance":"HIGH"},{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M17292","name":"Warfarin","asFound":"Third","relevance":"HIGH"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M490","name":"Dabigatran","asFound":"4 hours","relevance":"HIGH"},{"id":"M1271","name":"Acenocoumarol","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}